{
    "nctId": "NCT00963209",
    "briefTitle": "Tamoxifen Citrate in Patients With Breast Cancer",
    "officialTitle": "Tamoxifen Metabolism and the Impact of Tamoxifen Dose on the Level of the Active Metabolites in Endocrine Sensitive Breast Cancer Patients",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 140,
    "primaryOutcomeMeasure": "Determination of CYP2D6 genotype and determination of plasma concentrations of tamoxifen citrate and its metabolites (N-desmethyl-tamoxifen, 4-hydroxy-tamoxifen and endoxifen) under the 20 mg daily and 40 mg daily schedules",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of breast cancer\n\n  * Hormone-sensitive breast cancer defined as \\> 10% estrogen receptor and/or \\> 10% progesterone receptor positivity by immunohistochemistry\n* Receiving treatment with tamoxifen citrate and must be eligible for exposure to higher doses\n\nPATIENT CHARACTERISTICS:\n\n* No history of deep venous thrombosis or pulmonary embolism\n* No history of endometrial carcinoma\n* No known history of vaginal bleeding, endometriosis, endometrial hyperplasia, endometrial hypertrophy, and/or polyps\n* Not pregnant or nursing\n* No contraindication to tamoxifen citrate treatment\n* No known allergy to midazolam or dextromethorphan\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}